Tags : Research and Option

Pharma

Sarepta Signs a Two-Year Research and Option Agreement with Codiak

Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up […]Read More